Lever
Lifestyle
- Regular physical activity
- Weight management
- Stress reduction
- Adequate sleep
Blutwerte · Marker
HbA1c
Glykiertes Hämoglobin · Glycated Hemoglobin · A1c · Langzeitzucker
Stoffwechsel & Glukose
- Einheit:
- %
HbA1c quantifies the percentage of hemoglobin that is glycated, reflecting average blood glucose levels over the past 2-3 months.
Reference Ranges
Reference
4–5.6%
4
4.5
5.4
5.6
LowNormalHigh
Reference
Optimal
Unit · %Reference ranges may vary slightly by laboratory. No significant sex-specific differences.
Overview
Übersicht
HbA1c, or glycated hemoglobin, is a biomarker that reflects the average blood glucose levels over the past two to three months. It measures the percentage of hemoglobin molecules in the blood that are glycated, providing a long-term indicator of glycemic control. Clinically, HbA1c is crucial for diagnosing and managing diabetes, as elevated levels indicate chronic hyperglycemia and correlate with the risk of diabetes-related complications such as coronary heart disease and stroke. Researchers have found that HbA1c is also a valuable prognostic tool for assessing the risk of long-term complications in diabetic patients. In the context of athletic performance, biohacking, or longevity, maintaining optimal HbA1c levels is important for metabolic health and reducing the risk of chronic diseases. However, researchers observed that HbA1c levels can be influenced by factors such as anemia, kidney disease, and variations in erythrocyte lifespan, which can confound the interpretation of results. Therefore, it is important to consider these factors when evaluating HbA1c levels.
Klinische Bedeutung
Elevated HbA1c levels indicate poor glycemic control and increased risk of diabetes complications. Lower levels suggest better glucose management but may also indicate conditions like anemia.
Dynamics
Trend Interpretation
Rising Values
Progressively rising HbA1c values suggest worsening glycemic control. Re-test every 3 months if elevated.
Falling Values
Progressively falling HbA1c values indicate improved glycemic control.
Re-test Interval
3 months if outside optimal range
Etiology
Causes — High & Low
Cause
Elevated Levels
- Poor glycemic control
- Diabetes mellitus
- Chronic kidney disease
- Cushing's syndrome
- Hyperthyroidism
Cause
Low Levels
- Anemia
- Chronic liver disease
- Hemolytic anemia
- Acute blood loss
- Vitamin C or E supplementation
Protocol
How to Optimize
Lever
Nutrition
- Low glycemic index foods
- High fiber diet
- Reduced sugar intake
- Balanced macronutrients
Lever
Supplementation
- Chromium
- Berberine
- Alpha-lipoic acid
Note:
Consult a healthcare provider before starting any supplementation, especially if on medication.
Testing Guidelines
✓Fasting Not Required
✓Not Time-Sensitive
Testing Frequency
Every 3-6 months for individuals with diabetes, annually for others.
Interfering Factors
- Recent blood transfusion
- Hemoglobin variants
- Iron deficiency anemia
Related Peptides & Hormones
Insulin
hormone or peptideCorrelated with
Open Research Questions
Current research suggests that the reference ranges and optimal targets for HbA1c, particularly in populations with advanced chronic kidney disease, remain debated due to confounding factors that can bias results. Researchers have not yet established alternative glycemic biomarkers that are fully validated to replace HbA1c in these populations. Additionally, clinical questions regarding the long-term implications of varying HbA1c levels on complications in diverse patient groups remain unanswered.
22 Research Publications
2,169
Total Citations
5
Human/RCT
12.7
Avg. Influence
2024
Latest
Sort
Filter
01Top
#01
Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients.
ReviewInfluence68.0
1146
This review highlighted the significance of glycated hemoglobin (HbA1c) as a reliable biomarker for diagnosing and monitoring diabetes. Researchers found that HbA1c reflects long-term glycemic control and correlates with the risk of diabetes-related complications, including coronary heart disease and stroke.
02Top
#02
CLINICAL PRACTICE. Polycystic Ovary Syndrome.
Case ReportInfluence17.0
399
This case study examined a 22-year-old woman with symptoms of polycystic ovary syndrome (PCOS) and found that her glycated hemoglobin (HbA1c) level was 5.7%, indicating it was slightly above the normal range. Researchers observed that the patient had elevated testosterone levels and a body mass index (BMI) of 29, which are relevant factors in managing PCOS.
03Top
#03
Glycemic Monitoring and Management in Advanced Chronic Kidney Disease.
ReviewInfluence10.0
164
This study explored glycemic monitoring in patients with advanced chronic kidney disease (CKD) and found that HbA1c assessment can be biased due to CKD-related conditions. Researchers observed that despite its limitations, an HbA1c range of 7% to 8% is favorable for managing diabetes in this population.
04
#04
HbA1c and factors other than diabetes mellitus affecting it.
ReviewInfluence5.0
117
This review explored the factors affecting HbA1c levels beyond blood sugar, emphasizing its role as a key biomarker for assessing long-term glucose control. Researchers found that an HbA1c value below 7% can reduce microvascular complications in diabetic patients. The study also detailed the methods of measuring HbA1c and its clinical significance.
05
#05
Is There a Role for HbA1c in Pregnancy?
ReviewInfluence5.0
108
This article discussed the role of HbA1c testing during pregnancy and found that physiological changes can affect HbA1c levels. Researchers observed that while HbA1c is useful for monitoring diabetes outside of pregnancy, its role during pregnancy requires further investigation.
06
#06
Potential Biomarkers for Post-Stroke Cognitive Impairment: A Systematic Review and Meta-Analysis.
Meta-AnalysisInfluence6.0
107
This systematic review and meta-analysis evaluated various blood biomarkers for post-stroke cognitive impairment and found that HbA1c levels did not significantly differ between patients with and without cognitive impairment. Researchers suggested that other biomarkers like homocysteine and C-reactive protein may be more indicative of post-stroke cognitive issues.
07
#07
Glycated Hemoglobin (HbA1c) as a Biomarker for Diabetic Foot Peripheral Neuropathy.
ReviewInfluence1.0
69
This systematic review investigated the predictive value of HbA1c for diabetic peripheral neuropathy (DPN) and its complications. Researchers found that while HbA1c is a useful biomarker for diabetes diagnosis, further research is needed to standardize its use in assessing DPN outcomes.
08
#08
Protein glycation in diabetes mellitus.
ReviewInfluence1.0
18
This review discussed the role of glycated hemoglobin (HbA1c) as a key indicator of diabetes and its complications. Researchers found that HbA1c reflects chronic hyperglycemia and is associated with various diabetic complications, emphasizing the need for further research on glycated proteins.
09
#09
Emerging biosensor probes for glycated hemoglobin (HbA1c) detection.
ReviewInfluence1.0
15
This review focused on emerging biosensor technologies for detecting glycated hemoglobin (HbA1c) and found that these sensors offer significant advantages for glycemic monitoring. Researchers observed that nanomaterials enhance the sensitivity and selectivity of HbA1c detection, which could improve diabetes management.
10
#10
Trends in Quantification of HbA1c Using Electrochemical and Point-of-Care Analyzers.
Review
14
This review examined advancements in electrochemical and point-of-care analyzers for quantifying HbA1c. Researchers found that new technologies aim to improve detection speed and accuracy, addressing the limitations of traditional HbA1c measurement techniques.
Clinical Trials (3)
3
Total Trials
1,111
Total Enrolled
Pivotal Trial of a Digital Therapeutic for the Treatment of Type 2 Diabetes
Sponsor
Better Therapeutics
Enrollment
668
Started
2021
Primary outcome
The difference in the mean change from baseline in HbA1c at Day 90 between Intervention and Standard of Care groups
Type 2 Diabetes
Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
Sponsor
Merck Sharp & Dohme LLC
Enrollment
291
Started
2014
Primary outcome
Change From Baseline in Hemoglobin A1C (HbA1C) at Week 26 - Full Analysis Set (FAS Population Excluding Rescue Approach
Type 2 Diabetes Mellitus
A Study of the Effect of Ezetimibe on Glucose Metabolism in Type 2 Diabetics With Hypercholesterolemia (P06541)
Sponsor
Organon and Co
Enrollment
152
Started
2012
Primary outcome
Change in Glycated Hemoglobin (HbA1c) From Baseline
Hypercholesterolemia
Publication Trend
Research publications about HbA1c over time
10totalTrack your bloodwork in PepStack
Log lab results, track trends and optimize your biomarkers over time.
Legal Disclaimer
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer